SCHEMBL485837

SCHEMBL485837

O=C(NC1CCCC1)c1ccc2ccccc2c1OCc1ccc(SC(F)(F)F)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
CXCR2 P25025 2/20 0.48
CNR2 P34972 8/20 0.48
CNR1 P21554 7/20 0.48
SGMS2 Q8NHU3 1/20 0.47
MAOB P27338 1/20 0.44
DRD4 P21917 1/20 0.43
RAB9A P51151 2/20 0.42
KDM4E B2RXH2 1/20 0.42
NPC1 O15118 1/20 0.42
NR1I2 O75469 1/20 0.42
HPGD P15428 1/20 0.42
AHR P35869 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
ABHD12 Q8N2K0 1/20 0.41
IDH1 O75874 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL485894 0.98 CXCR2 (0.48) ALDH1A1MEN1KMT2ACXCR2CNR2
Formic Acid SCHEMBL27693239 0.94 CXCR2 (0.47) ALDH1A1MEN1KMT2ACXCR2CNR2
SCHEMBL485511 0.87 CXCR2 (0.62) ALDH1A1MEN1KMT2ACXCR2CNR2
SCHEMBL23460958 0.87 CXCR2 (0.46) ALDH1A1MEN1KMT2ACXCR2CNR2
SCHEMBL23460956 0.87 CXCR2 (0.46) ALDH1A1MEN1KMT2ACXCR2CNR2
SCHEMBL486231 0.86 CXCR2 (0.52) ALDH1A1MEN1KMT2ACXCR2CNR2
SCHEMBL485551 0.85 ALDH1A1 (0.49) ALDH1A1MEN1KMT2ACXCR2CNR2
SCHEMBL485699 0.85 CXCR2 (0.62) ALDH1A1MEN1KMT2ACXCR2CNR2
SCHEMBL485455 0.83 CXCR2 (0.49) ALDH1A1MEN1KMT2ACXCR2CNR2
Formic Acid SCHEMBL27693212 0.82 CXCR2 (0.50) ALDH1A1MEN1KMT2ACXCR2CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836158-B1 FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION SANOFI AVENTIS DEUTSCHLAND (DE) 2012-02-01 EP claimed